ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

APLS Apellis Pharmaceuticals Inc

41.04
0.71 (1.76%)
Last Updated: 10:16:35
Delayed by 15 minutes

Period:

Draw Mode:

Volume 146,854
Bid Price 40.99
Ask Price 41.10
News -
Day High 41.19

Low
19.8301

52 Week Range

High
92.61

Day Low 40.00
Share Name Share Symbol Market Stock Type
Apellis Pharmaceuticals Inc APLS NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.71 1.76% 41.04 10:16:35
Open Price Low Price High Price Close Price Previous Close
40.31 40.00 41.19 40.33
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
2,780 146,854 US$ 40.52 US$ 5,951,211 - 19.8301 - 92.61
Last Trade Type Quantity Price Currency
10:16:50 3 US$ 41.02 USD

Apellis Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
4.92B 120.58M - 396.59M -525.63M -4.36 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Apellis Pharmaceuticals News

Date Time Source News Article
6/10/202406:00GlobeNewswire Inc.SYFOVRE® (pegcetacoplan injection) Preserved Visual Function..
6/05/202415:50Edgar (US Regulatory)Form 8-K - Current report
6/05/202406:00GlobeNewswire Inc.Apellis Pharmaceuticals to Host a Fireside Chat at the..
5/24/202409:00GlobeNewswire Inc.Positive One-Year Data from Phase 2 Study of Pegcetacoplan..
5/21/202415:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/14/202407:09Edgar (US Regulatory)Form 8-K - Current report
5/14/202407:00GlobeNewswire Inc.Apellis Pharmaceuticals Refinances Existing Debt with Up to..
5/09/202416:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/08/202416:13Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
5/07/202406:05GlobeNewswire Inc.Apellis Pharmaceuticals Reports First Quarter 2024 Financial..
5/07/202406:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
5/06/202406:00GlobeNewswire Inc.Apellis Pharmaceuticals to Host a Fireside Chat at the Bank..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No APLS Message Board. Create One! See More Posts on APLS Message Board See More Message Board Posts

Historical APLS Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week41.5343.7640.0041.94804,881-0.49-1.18%
1 Month43.1543.9938.3541.031,085,337-2.11-4.89%
3 Months56.3259.9138.218846.281,377,635-15.28-27.13%
6 Months52.3773.8038.218856.321,507,122-11.33-21.63%
1 Year88.4192.6119.830146.862,627,824-47.37-53.58%
3 Years58.9194.7519.830151.051,766,237-17.87-30.33%
5 Years22.1394.7516.8547.541,385,80618.9185.45%

Apellis Pharmaceuticals Description

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.

Your Recent History

Delayed Upgrade Clock